Fibronectin and tenascin-C: Accomplices in vascular morphogenesis during development and tumor growth

International Journal of Developmental Biology

Volumn 55, Issue 4-5, 2011, Pages 511-525

  van Obberghen Schilling, Ellen ^a,b   Tucker, Richard P ^c   Saupe, Falk ^d   Gasser, Isabelle ^d   Cseh, Botond ^a,b   Orend, Gertraud ^d,e,f  

^a CENTRE DE BIOCHIMIE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INSERM   (France)

^e UNIVERSITÉ DE STRASBOURG   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Fibronectin; Matrix assembly; Tenascin C; Tumor angiogenesis

Indexed keywords

FIBRONECTIN; FIBRONECTIN RECEPTOR; TENASCIN;

ANGIOGENESIS; ARTICLE; CELL ADHESION; DEVELOPMENTAL BIOLOGY; EXTRACELLULAR MATRIX; GENE DELETION; GENE INACTIVATION; METASTASIS; MOLECULAR EVOLUTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR VASCULARIZATION; VASCULARIZATION;

ANIMALS; BIOLOGICAL EVOLUTION; CELL ADHESION; FIBRONECTINS; HUMANS; MODELS, BIOLOGICAL; MORPHOGENESIS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; SIGNAL TRANSDUCTION; TENASCIN;

EID: 79960993177     PISSN: 02146282     EISSN: None     Source Type: Journal    
DOI: 10.1387/ijdb.103243eo     Document Type: Article

References (179)

1. AMBORT, D., BRELLIER, F., BECKER-PAULY, C., STOCKER, W., ANDREJEVIC-BLANT, S., CHIQUET, M. and STERCHI, E.E. (2010). Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading. Matrix Biol 29: 31-42.
2. ASTROF, S., CROWLEY, D. and HYNES, R.O. (2007a). Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin. Dev Biol 311: 11-24.
3. ASTROF, S. and HYNES, R.O. (2009). Fibronectins in vascular morphogenesis. Angiogenesis 12: 165-175.
4. ASTROF, S., KIRBY, A., LINDBLAD-TOH, K., DALY, M. and HYNES, R.O. (2007b). Heart development in fibronectin-null mice is governed by a genetic modifier on chromosome four. Mech Dev 124: 551-558.
5. AVRAAMIDES, C.J., GARMY-SUSINI, B. and VARNER, J.A. (2008). Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 8: 604-617.
6. BACIU, P.C., SAONCELLA, S., LEE, S.H., DENHEZ, F., LEUTHARDT, D. and GOETINCK, P.F. (2000). Syndesmos, a protein that interacts with the cytoplasmic domain of syndecan-4, mediates cell spreading and actin cytoskeletal organization. J Cell Sci 113: 315-324.
7. BAJOGHLI, B., AGHAALLAEI, N., HESS, I., RODE, I., NETUSCHIL, N., TAY, B.H., VENKATESH, B., YU, J.K., KALTENBACH, S.L., HOLLAND, N.D. et al. (2009). Evolution of genetic networks underlying the emergence of thymopoiesis in vertebrates. Cell 138: 186-197.
8. BALLARD, V.L., SHARMA, A., DUIGNAN, I., HOLM, J.M., CHIN, A., CHOI, R., HAJJAR, K.A., WONG, S.C. and EDELBERG, J.M. (2006). Vascular tenascin-C regulates cardiac endothelial phenotype and neovascularization. FASEB J 20: 717-719.
9. BALZA, E., SASSI, F., VENTURA, E., PARODI, A., FOSSATI, S., BLALOCK, W., CARNEMOLLA, B., CASTELLANI, P., ZARDI, L. and BORSI, L. (2009). A novel human fibronectin cryptic sequence unmasked by the insertion of the angiogenesis-associated extra type III domain B. Int J Cancer 125: 751-758.
10. BAZIGOU, E., XIE, S., CHEN, C., WESTON, A., MIURA, N., SOROKIN, L., ADAMS, R., MURO, A.F., SHEPPARD, D. and MAKINEN, T. (2009). Integrin-alpha9 is required for fibronectin matrix assembly during lymphatic valve morphogenesis. Dev Cell 17: 175-186.
11. BENCHARIT, S., CUI, C.B., SIDDIQUI, A., HOWARD-WILLIAMS, E.L., SONDEK, J., ZUOBI-HASONA, K. and AUKHIL, I. (2007). Structural insights into fibronectin type III domain-mediated signaling. J Mol Biol 367: 303-309.
12. BENTLEY, A.A. and ADAMS, J.C. (2010). The evolution of thrombospondins and their ligand-binding activities. Mol Biol Evol 27: 2187-2197.
13. BENTLEY, K., GERHARDT, H. and BATES, P.A. (2008). Agent-based simulation of notch-mediated tip cell selection in angiogenic sprout initialisation. J Theor Biol 250: 25-36.
14. BERNDT, A., KOLLNER, R., RICHTER, P., FRANZ, M., VOIGT, A., BORSI, L., GIAVAZZI, R., NERI, D. and KOSMEHL, H. (2010). A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol 133: 467-475.
15. BETZ, P., NERLICH, A., TUBEL, J., PENNING, R. and EISENMENGER, W. (1993). Localization of tenascin in human skin wounds-an immunohistochemical study. Int J Legal Med 105: 325-328.
16. BOURDON, M.A., WIKSTRAND, C.J., FURTHMAYR, H., MATTHEWS, T.J. and BIGNER, D.D. (1983). Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res 43: 2796-2805.
17. CALVO, A., CATENA, R., NOBLE, M.S., CARBOTT, D., GIL-BAZO, I., GONZALEZ-MORENO, O., HUH, J.I., SHARP, R., QIU, T.H., ANVER, M.R. et al. (2008). Identification of VEGF-regulated genes associated with increased lung metastatic potential: functional involvement of tenascin-C in tumor growth and lung metastasis. Oncogene 27: 5373-5384.
18. CANFIELD, A.E. and SCHOR, A.M. (1995). Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 108 (Pt 2): 797-809.
19. CARMELIET, P. (2000). Mechanisms of angiogenesis and arteriogenesis. Nat Med 6: 389-395.
20. CARNEMOLLA, B., LEPRINI, A., ALLEMANNI, G., SAGINATI, M. and ZARDI, L. (1992). The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence. J Biol Chem 267: 24689-24692.
21. CASTELLETTI, F., DONADELLI, R., BANTERLA, F., HILDEBRANDT, F., ZIPFEL, P.F., BRESIN, E., OTTO, E., SKERKA, C., RENIERI, A., TODESCHINI, M. et al. (2008). Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proc Natl Acad Sci USA 105: 2538-2543.
22. CASTELLON, R., CABALLERO, S., HAMDI, H.K., ATILANO, S.R., AOKI, A.M., TARNUZZER, R.W., KENNEY, M.C., GRANT, M.B. and LJUBIMOV, A.V. (2002). Effects of tenascin-C on normal and diabetic retinal endothelial cells in culture. Invest Ophthalmol Vis Sci 43: 2758-2766.
23. CASTILLEJO-LOPEZ, C., ARIAS, W.M. and BAUMGARTNER, S. (2004). The fat-like gene of Drosophila is the true orthologue of vertebrate fat cadherins and is involved in the formation of tubular organs. J Biol Chem 279: 24034-24043.
24. CHAKRAVARTI, R. and ADAMS, J.C. (2006). Comparative genomics of the syndecans defines an ancestral genomic context associated with matrilins in vertebrates. BMC Genomics 7: 83.
25. CHIQUET-EHRISMANN, R. and CHIQUET, M. (2003). Tenascins: regulation and putative functions during pathological stress. J Pathol 200: 488-499.
26. CHIQUET-EHRISMANN, R., KALLA, P., PEARSON, C.A., BECK, K. and CHIQUET, M. (1988). Tenascin interferes with fibronectin action. Cell 53: 383-390.
27. CHIQUET-EHRISMANN, R., MATSUOKA, Y., HOFER, U., SPRING, J., BERNASCONI, C. and CHIQUET, M. (1991). Tenascin variants: differential binding to fibronectin and distinct distribution in cell cultures and tissues. Cell Regul 2: 927-938.
28. CHIQUET, M. and FAMBROUGH, D.M. (1984). Chick myotendinous antigen. II. A novel extracellular glycoprotein complex consisting of large disulfide-linked subunits. J Cell Biol 98: 1937-1946.
29. CHIQUET, M., VRUCINIC-FILIPI, N., SCHENK, S., BECK, K. and CHIQUET-EHRISMANN, R. (1991). Isolation of chick tenascin variants and fragments. A C-terminal heparin-binding fragment produced by cleavage of the extra domain from the largest subunit splicing variant. Eur J Biochem 199: 379-388.
30. CHUNG, C.Y. and ERICKSON, H.P. (1997). Glycosaminoglycans modulate fibronectin matrix assembly and are essential for matrix incorporation of tenascin-C. J Cell Sci 110 (Pt 12): 1413-1419.
31. CHUNG, C.Y., MURPHY-ULLRICH, J.E. and ERICKSON, H.P. (1996). Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 7: 883-892.
32. CHUNG, C.Y., ZARDI, L. and ERICKSON, H.P. (1995). Binding of tenascin-C to soluble fibronectin and matrix fibrils. J Biol Chem 270: 29012-29017.
33. CIMA, F., PERIN, A., BURIGHEL, P. and BALLARIN, L. (2001). Morpho-functional characterization of haemocytes of the compound ascidian Botrylloides leachi (Tunicata, Ascidiacea). Acta Zool. 82: 261-274.
34. CLINES, G.A., MOHAMMAD, K.S., BAO, Y., STEPHENS, O.W., SUVA, L.J., SHAUGHNESSY, J.D. JR., FOX, J.W., CHIRGWIN, J.M. and GUISE, T.A. (2007). Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 21: 486-498.
35. CSEH, B., FERNANDEZ-SAUZE, S., GRALL, D., SCHAUB, S., DOMA, E. and VAN OBBERGHEN-SCHILLING, E. (2010). Autocrine fibronectin directs matrix assembly and crosstalk between cell-matrix and cell-cell adhesion in vascular endothelial cells. J Cell Sci 123: 3989-3999.
36. CUENI, L.N., HEGYI, I., SHIN, J.W., ALBINGER-HEGYI, A., GRUBER, S., KUNSTFELD, R., MOCH, H. and DETMAR, M. (2010). Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin. Am J Pathol 177: 1004-1016.
37. DALLAS, S.L., CHEN, Q. and SIVAKUMAR, P. (2006). Dynamics of assembly and reorganization of extracellular matrix proteins. Curr Top Dev Biol 75: 1-24.
38. DANEN, E.H., AOTA, S., VAN KRAATS, A.A., YAMADA, K.M., RUITER, D.J. and VAN MUIJEN, G.N. (1995). Requirement for the synergy site for cell adhesion to fibronectin depends on the activation state of integrin alpha 5 beta 1. J Biol Chem 270: 21612-21618.
39. DAVIDSON, B. (2007). Ciona intestinalis as a model for cardiac development. Semin Cell Dev Biol 18: 16-26.
40. DE LANGHE, S.P., SALA, F.G., DEL MORAL, P.M., FAIRBANKS, T.J., YAMADA, K.M., WARBURTON, D., BURNS, R.C. and BELLUSCI, S. (2005). Dickkopf-1 (DKK1) reveals that fibronectin is a major target of Wnt signaling in branching morphogenesis of the mouse embryonic lung. Dev Biol 277: 316-331.
41. DE WEVER, O., NGUYEN, Q.D., VAN HOORDE, L., BRACKE, M., BRUYNEEL, E., GESPACH, C. and MAREEL, M. (2004). Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. FASEB J 18: 1016-1018.
42. DEGEN, M., BRELLIER, F., KAIN, R., RUIZ, C., TERRACCIANO, L., OREND, G. and CHIQUET-EHRISMANN, R. (2007). Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Res 67: 9169-9179.
43. DEGEN, M., BRELLIER, F., SCHENK, S., DRISCOLL, R., ZAMAN, K., STUPP, R., TORNILLO, L., TERRACCIANO, L., CHIQUET-EHRISMANN, R., RUEGG, C. et al. (2008). Tenascin-W, a new marker of cancer stroma, is elevated in sera of colon and breast cancer patients. Int J Cancer 122: 2454-2461.
44. DESGROSELLIER, J.S. and CHERESH, D.A. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10: 9-22.
45. DOME, B., HENDRIX, M.J., PAKU, S., TOVARI, J. and TIMAR, J. (2007). Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 170: 1-15.
46. DOOLITTLE, R.F. (2009). Step-by-step evolution of vertebrate blood coagulation. Cold Spring Harb Symp Quant Biol 74: 35-40.
47. DRUMEA-MIRANCEA, M., WESSELS, J.T., MULLER, C.A., ESSL, M., EBLE, J.A., TOLOSA, E., KOCH, M., REINHARDT, D.P., SIXT, M., SOROKIN, L. et al. (2006). Characterization of a conduit system containing laminin-5 in the human thymus: a potential transport system for small molecules. J Cell Sci 119: 1396-1405.
48. DUECK, M., RIEDL, S., HINZ, U., TANDARA, A., MOLLER, P., HERFARTH, C. and FAISSNER, A. (1999). Detection of tenascin-C isoforms in colorectal mucosa, ulcerative colitis, carcinomas and liver metastases. Int J Cancer 82: 477-483.
49. EBNER, B., BURMESTER, T. and HANKELN, T. (2003). Globin genes are present in Ciona intestinalis. Mol Biol Evol 20: 1521-1525.
50. EGEBLAD, M., NAKASONE, E.S. and WERB, Z. (2010). Tumors as organs: complex tissues that interface with the entire organism. Dev Cell 18: 884-901.
51. EL HALLANI, S., BOISSELIER, B., PEGLION, F., ROUSSEAU, A., COLIN, C., IDBAIH, A., MARIE, Y., MOKHTARI, K., THOMAS, J.L., EICHMANN, A. et al.''(2010). A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry. Brain 133: 973-982.
52. ERLER, J.T. and WEAVER, V.M. (2009). Three-dimensional context regulation of metastasis. Clin Exp Metastasis 26: 35-49.
53. EXPOSITO, J.Y., LARROUX, C., CLUZEL, C., VALCOURT, U., LETHIAS, C. and DEGNAN, B.M. (2008). Demosponge and sea anemone fibrillar collagen diversity reveals the early emergence of A/C clades and the maintenance of the modular structure of type V/XI collagens from sponge to human. J Biol Chem 283: 28226-28235.
54. FAISSNER, A., KRUSE, J., CHIQUET-EHRISMANN, R. and MACKIE, E. (1988). The high-molecular-weight J1 glycoproteins are immunochemically related to tenascin. Differentiation 37: 104-114.
55. FASSLER, R., SASAKI, T., TIMPL, R., CHU, M.L. and WERNER, S. (1996). Differential regulation of fibulin, tenascin-C, and nidogen expression during wound healing of normal and glucocorticoid-treated mice. Exp Cell Res 222: 111-116.
56. FFRENCH-CONSTANT, C. and HYNES, R.O. (1989). Alternative splicing of fibronectin is temporally and spatially regulated in the chicken embryo. Development 106: 375-388.
57. FISCHER, D., CHIQUET-EHRISMANN, R., BERNASCONI, C. and CHIQUET, M. (1995). A single heparin binding region within the fibrinogen-like domain is functional in chick tenascin-C. J Biol Chem 270: 3378-3384.
58. FISCHER, J.W. (2007). Tenascin-C: a key molecule in graft stenosis. Cardiovasc Res 74: 335-336.
59. FOGELGREN, B., POLGAR, N., SZAUTER, K.M., UJFALUDI, Z., LACZKO, R., FONG, K.S. and CSISZAR, K. (2005). Cellular fibronectin binds to lysyl oxidase with high affinity and is critical for its proteolytic activation. J Biol Chem 280: 24690-24697.
60. FORSBERG, E., HIRSCH, E., FROHLICH, L., MEYER, M., EKBLOM, P., ASZODI, A., WERNER, S. and FASSLER, R. (1996). Skin wounds and severed nerves heal normally in mice lacking tenascin-C. Proc Natl Acad Sci USA 93: 6594-6599.
61. FRANCIS, S.E., GOH, K.L., HODIVALA-DILKE, K., BADER, B.L., STARK, M., DAVIDSON, D. and HYNES, R.O. (2002). Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 22: 927-933.
62. FRANCO, C.A., LIEBNER, S. and GERHARDT, H. (2009). Vascular morphogenesis: a Wnt for every vessel? Curr Opin Genet Dev 19: 476-483.
63. GAGGIOLI, C., HOOPER, S., HIDALGO-CARCEDO, C., GROSSE, R., MARSHALL, J.F., HARRINGTON, K. and SAHAI, E. (2007). Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9: 1392-1400.
64. GARCION, E., FAISSNER, A. and FFRENCH-CONSTANT, C. (2001). Knockout mice reveal a contribution of the extracellular matrix molecule tenascin-C to neural precursor proliferation and migration. Development 128: 2485-2496.
65. GARMY-SUSINI, B., AVRAAMIDES, C.J., SCHMID, M.C., FOUBERT, P., ELLIES, L.G., BARNES, L., FERAL, C., PAPAYANNOPOULOU, T., LOWY, A., BLAIR, S.L. et al. (2010). Integrin alpha4beta1 signaling is required for lymphangiogenesis and tumor metastasis. Cancer Res 70: 3042-3051.
66. GEBOES, K., EL-ZINE, M.Y., DALLE, I., EL-HADDAD, S., RUTGEERTS, P. and VAN EYKEN, P. (2001). Tenascin and strictures in inflammatory bowel disease: an immunohistochemical study. Int J Surg Pathol 9: 281-286.
67. GEORGE, E.L., BALDWIN, H.S. and HYNES, R.O. (1997). Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 90: 3073-3081.
68. GEORGE, E.L., GEORGES-LABOUESSE, E.N., PATEL-KING, R.S., RAYBURN, H. and HYNES, R.O. (1993). Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119: 1079-1091.
69. GERHARDT, H., GOLDING, M., FRUTTIGER, M., RUHRBERG, C., LUNDKVIST, A., ABRAMSSON, A., JELTSCH, M., MITCHELL, C., ALITALO, K., SHIMA, D. et al. (2003). VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia. J Cell Biol 161: 1163-1177.
70. GINDRE, D., PEYROL, S., RACCURT, M., SOMMER, P., LOIRE, R., GRIMAUD, J.A. and CORDIER, J.F. (1995). Fibrosing vasculitis in Wegener's granulomatosis: ultrastructural and immunohistochemical analysis of the vascular lesions. Virchows Arch 427: 385-393.
71. GRIMSHAW, M.J. (2007). Endothelins and hypoxia-inducible factor in cancer. Endocr Relat Cancer 14: 233-244.
72. GUTTERY, D.S., SHAW, J.A., LLOYD, K., PRINGLE, J.H. and WALKER, R.A. (2010). Expression of tenascin-C and its isoforms in the breast. Cancer Metastasis Rev 29: 595-606.
73. HASHIMOTO-UOSHIMA, M., YAN, Y.Z., SCHNEIDER, G. and AUKHIL, I. (1997). The alternatively spliced domains EIIIB and EIIIA of human fibronectin affect cell adhesion and spreading. J Cell Sci 110: 2271-2280.
74. HAUZENBERGER, D., OLIVIER, P., GUNDERSEN, D. and RUEGG, C. (1999). Tenascin-C inhibits beta1 integrin-dependent T lymphocyte adhesion to fibronectin through the binding of its fnIII 1-5 repeats to fibronectin. Eur J Immunol 29: 1435-1447.
75. HELLEMAN, J., JANSEN, M.P., RUIGROK-RITSTIER, K., VAN STAVEREN, I.L., LOOK, M.P., MEIJER-VAN GELDER M.E., SIEUWERTS, A.M., KLIJN, J.G., SLEIJFER, S., FOEKENS, J.A. et al. (2008). Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res 14: 5555-5564.
76. HENDRIX, M.J., SEFTOR, E.A., HESS, A.R. and SEFTOR, R.E. (2003). Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nat Rev Cancer 3: 411-421.
77. HILLEN, F. and GRIFFIOEN, A.W. (2007). Tumour vascularization: sprouting angiogenesis and beyond. Cancer Metastasis Rev 26: 489-502.
78. HODIVALA-DILKE, K. (2008). alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol 20: 514-519.
79. HUANG, G., XIE, X., HAN, Y., FAN, L., CHEN, J., MOU, C., GUO, L., LIU, H., ZHANG, Q., CHEN, S. et al. (2007). The identification of lymphocyte-like cells and lymphoid-related genes in amphioxus indicates the twilight for the emergence of adaptive immune system. PLoS One 2: e206.
80. HUANG, G., ZHANG, Y., KIM, B., GE, G., ANNIS, D.S., MOSHER, D.F. and GREENSPAN, D.S. (2009). Fibronectin binds and enhances the activity of bone morphogenetic protein 1. J Biol Chem 284: 25879-25888.
81. HUANG, W., CHIQUET-EHRISMANN, R., MOYANO, J.V., GARCIA-PARDO, A. and OREND, G. (2001). Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 61: 8586-8594.
82. HUANG, X.Z., WU, J.F., FERRANDO, R., LEE, J.H., WANG, Y.L., FARESE, R.V. JR. and SHEPPARD, D. (2000). Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol 20: 5208-5215.
83. HUIJBERS, E.J., RINGVALL, M., FEMEL, J., KALAMAJSKI, S., LUKINIUS, A., ABRINK, M., HELLMAN, L. and OLSSON, A.K. (2010). Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J. 24: 4535-4544
84. HUMPHRIES, J.D., BYRON, A. and HUMPHRIES, M.J. (2006). Integrin ligands at a glance. J Cell Sci 119: 3901-3903.
85. HUVENEERS, S., TRUONG, H., FASSLER, R., SONNENBERG, A. and DANEN, E.H. (2008). Binding of soluble fibronectin to integrin alpha5 beta1 - link to focal adhesion redistribution and contractile shape. J Cell Sci 121: 2452-2462.
86. HYNES, R.O. (2007). Cell-matrix adhesion in vascular development. J Thromb Haemost 5 Suppl 1: 32-40.
87. HYNES, R.O. (2009). The extra cellular matrix: not just pretty fibrils. Science 326: 1216-1219.
88. INGBER, D.E. (2002). Mechanical signaling and the cellular response to extra cellular matrix in angiogenesis and cardiovascular physiology. Circ Res 91: 877-887.
89. INGHAM, K.C., BREW, S.A. and ERICKSON, H.P. (2004). Localization of a cryptic binding site for tenascin on fibronectin. J Biol Chem 279: 28132-28135.
90. JALLO, G.I., FRIEDLANDER, D.R., KELLY, P.J., WISOFF, J.H., GRUMET, M. and ZAGZAG, D. (1997). Tenascin-C expression in the cyst wall and fluid of human brain tumors correlates with angiogenesis. Neurosurgery 41: 1052-1059.
91. JIANG, B., LIOU, G.I., BEHZADIAN, M.A. and CALDWELL, R.B. (1994). Astrocytes modulate retinal vasculogenesis: effects on fibronectin expression. J Cell Sci 107: 2499-2508.
92. KAARIAINEN, E., NUMMELA, P., SOIKKELI, J., YIN, M., LUKK, M., JAHKOLA, T., VIROLAINEN, S., ORA, A., UKKONEN, E., SAKSELA, O. et al. (2006). Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol 210: 181-191.
93. KASPAR, M., ZARDI, L. and NERI, D. (2006). Fibronectin as target for tumor therapy. Int J Cancer 118: 1331-1339.
94. KAWASHIMA, T., KAWASHIMA, S., TANAKA, C., MURAI, M., YONEDA, M., PUTNAM, N.H., ROKHSAR, D.S., KANEHISA, M., SATOH, N. and WADA, H. (2009). Domain shuffling and the evolution of vertebrates. Genome Res 19: 1393-1403.
95. KII, I., NISHIYAMA, T., LI, M., MATSUMOTO, K., SAITO, M., AMIZUKA, N. and KUDO, A. (2010). Incorporation of tenascin-C into the extracellular matrix by periostin underlies an extracellular meshwork architecture. J Biol Chem 285: 2028-2039.
96. KINSELLA, M.G., FISCHER, J.W., MASON, D.P. and WIGHT, T.N. (2000). Retrovirallymediated expression of decorin by macrovascular endothelial cells. Effects on cellular migration and fibronectin fibrillogenesis in vitro. J Biol Chem 275: 13924-13932.
97. KOHAN, M., MURO, A.F., WHITE, E.S. and BERKMAN, N. (2010). EDA-containing cellular fibronectin induces fibroblast differentiation through binding to {alpha}4{beta}7 integrin receptor and MAPK/Erk 1/2-dependent signaling. FASEB J 24:4503-4512.
98. KUCERA, T. and LAMMERT, E. (2009). Ancestral vascular tube formation and its adoption by tumors. Biol Chem 390: 985-994.
99. KUCERA, T., STRILIC, B., REGENER, K., SCHUBERT, M., LAUDET, V. and LAMMERT, E. (2009). Ancestral vascular lumen formation via basal cell surfaces. PLoS ONE 4: e4132.
100. LANGE, K., KAMMERER, M., HEGI, M.E., GROTEGUT, S., DITTMANN, A., HUANG, W., FLURI, E., YIP, G.W., GOTTE, M., RUIZ, C. et al. (2007). Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res 67: 6163-6173.
101. LANGE, K., KAMMERER, M., SAUPE, F., HEGI, M.E., GROTEGUT, S., FLURI, E. and OREND, G. (2008). Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res 68: 6942-6952.
102. LATIJNHOUWERS, M.A., BERGERS, M., VAN BERGEN, B.H., SPRUIJT, K.I., ANDRIESSEN, M.P. and SCHALKWIJK, J. (1996). Tenascin expression during wound healing in human skin. J Pathol 178: 30-35.
103. LEGATE, K.R., MONTANEZ, E., KUDLACEK, O. and FASSLER, R. (2006). ILK, PINCH and parvin: the tIPP of integrin signalling. Nat Rev Mol Cell Biol 7: 20-31.
104. LEISS, M., BECKMANN, K., GIROS, A., COSTELL, M. and FASSLER, R. (2008). The role of integrin binding sites in fibronectin matrix assembly in vivo. Curr Opin Cell Biol 20: 502-507.
105. LIAO, Y.F., GOTWALS, P.J., KOTELIANSKY, V.E., SHEPPARD, D. and VAN DE WATER, L. (2002). The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem 277: 14467-14474.
106. LIGHTNER, V.A. and ERICKSON, H.P. (1990). Binding of hexabrachion (tenascin) to the extracellular matrix and substratum and its effect on cell adhesion. J Cell Sci 95: 263-277.
107. LINDER, E., VAHERI, A., RUOSLAHTI, E. and WARTIOVAARA, J. (1975). Distribution of fibroblast surface antigen in the developing chick embryo. J Exp Med 142: 41-9.
108. LOKMIC, Z., LAMMERMANN, T., SIXT, M., CARDELL, S., HALLMANN, R. and SOROKIN, L. (2008). The extracellular matrix of the spleen as a potential organizer of immune cell compartments. Semin Immunol 20: 4-13.
109. MACKIE, E.J. (1997). Molecules in focus: tenascin-C. Int J Biochem Cell Biol 29: 1133-1137.
110. MACKIE, E.J., HALFTER, W. and LIVERANI, D. (1988). Induction of tenascin in healing wounds. J Cell Biol 107: 2757-2767.
111. MANTOVANI, A., ROMERO, P., PALUCKA, A.K. and MARINCOLA, F.M. (2008). Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 371: 771-783.
112. MAO, Y. and SCHWARZBAUER, J.E. (2005). Fibronectin fibrillogenesis, a cell-mediated matrix assembly process. Matrix Biol 24: 389-399.
113. MARTINO, M.M. and HUBBELL, J.A. (2010). The 12th-14th type III repeats of fibronectin function as a highly promiscuous growth factor-binding domain. FASEB J 24:4711-4721.
114. MIDWOOD, K.S., MAO, Y., HSIA, H.C., VALENICK, L.V. and SCHWARZBAUER, J.E. (2006). Modulation of cell-fibronectin matrix interactions during tissue repair. J Investig Dermatol Symp Proc 11: 73-78.
115. MIDWOOD, K.S. and OREND, G. (2009). The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 3: 287-310.
116. MIDWOOD, K.S. and SCHWARZBAUER, J.E. (2002). Tenascin-C modulates matrix contraction via focal adhesion kinase- and Rho-mediated signaling pathways. Mol Biol Cell 13: 3601-3613.
117. MIDWOOD, K.S., VALENICK, L.V., HSIA, H.C. and SCHWARZBAUER, J.E. (2004a). Coregulation of fibronectin signaling and matrix contraction by tenascin-C and syndecan-4. Mol Biol Cell 15: 5670-5677.
118. MIDWOOD, K.S., WILLIAMS, L.V. and SCHWARZBAUER, J.E. (2004b). Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol 36: 1031-1037.
119. MINN, A.J., GUPTA, G.P., SIEGEL, P.M., BOS, P.D., SHU, W., GIRI, D.D., VIALE, A., OLSHEN, A.B., GERALD, W.L. and MASSAGUE, J. (2005). Genes that mediate breast cancer metastasis to lung. Nature 436: 518-524.
120. MITROVIC, N. and SCHACHNER, M. (1995). Detection of tenascin-C in the nervous system of the tenascin-C mutant mouse. J Neurosci Res 42: 710-717.
121. MIYAMOTO, S., TERAMOTO, H., GUTKIND, J.S. and YAMADA, K.M. (1996). Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol 135: 1633-1642.
122. MOSHER, D.F., SCHAD, P.E. and VANN, J.M. (1980). Cross-linking of collagen and fibronectin by factor XIIIa. Localization of participating glutaminyl residues to a tryptic fragment of fibronectin. J Biol Chem 255: 1181-1188.
123. MURPHY-ULLRICH, J.E., LIGHTNER, V.A., AUKHIL, I., YAN, Y.Z., ERICKSON, H.P. and HOOK, M. (1991). Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 115: 1127-1136.
124. NERI, D. and BICKNELL, R. (2005). Tumour vascular targeting. Nat Rev Cancer 5: 436-446.
125. NGUYEN, A., THORIN-TRESCASES, N. and THORIN, E. (2010). Working under pressure: coronary arteries and the endothelin system. Am J Physiol Regul Integr Comp Physiol 298: R1188-1194.
126. OREND, G. (2005). Potential oncogenic action of tenascin-C in tumorigenesis. Int J Biochem Cell Biol 37: 1066-1083.
127. OREND, G. and CHIQUET-EHRISMANN, R. (2006). Tenascin-C induced signaling in cancer. Cancer Lett 244: 143-163.
128. OREND, G., HUANG, W., OLAYIOYE, M.A., HYNES, N.E. and CHIQUET-EHRISMANN, R. (2003). Tenascin-C blocks cell-cycle progression of anchorage-dependent fibroblasts on fibronectin through inhibition of syndecan-4. Oncogene 22: 3917-3926.
129. PAEZ-RIBES, M., ALLEN, E., HUDOCK, J., TAKEDA, T., OKUYAMA, H., VINALS, F., INOUE, M., BERGERS, G., HANAHAN, D. and CASANOVAS, O. (2009). Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15: 220-231.
130. PAIK, D.C., FU, C., BHATTACHARYA, J. and TILSON, M.D. (2004). Ongoing angiogenesis in blood vessels of the abdominal aortic aneurysm. Exp Mol Med 36: 524-533.
131. PANKOV, R. and YAMADA, K.M. (2002). Fibronectin at a glance. J Cell Sci 115: 3861-3863.
132. PAULIS, Y.W., SOETEKOUW, P.M., VERHEUL, H.M., TJAN-HEIJNEN, V.C. and GRIFFIOEN, A.W. (2010). Signalling pathways in vasculogenic mimicry. Biochim Biophys Acta 1806: 18-28.
133. PEDRETTI, M., RANCIC, Z., SOLTERMANN, A., HERZOG, B.A., SCHLIEMANN, C., LACHAT, M., NERI, D. and KAUFMANN, P.A. (2010). Comparative immunohistochemical staining of atherosclerotic plaques using F16, F8 and L19: Three clinical-grade fully human antibodies. Atherosclerosis 208: 382-389.
134. PEDRETTI, M., SOLTERMANN, A., ARNI, S., WEDER, W., NERI, D. and HILLINGER, S. (2009). Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer 64: 28-33.
135. PETERS, J.H., CHEN, G.E. and HYNES, R.O. (1996). Fibronectin isoform distribution in the mouse. II. Differential distribution of the alternatively spliced EIIIB, EIIIA, and V segments in the adult mouse. Cell Adhes Commun 4: 127-148.
136. PETERS, J.H. and HYNES, R.O. (1996). Fibronectin isoform distribution in the mouse. I. The alternatively spliced EIIIB, EIIIA, and V segments show widespread codistribution in the developing mouse embryo. Cell Adhes Commun 4: 103-125.
137. POLLARD, J.W. (2008). Macrophages define the invasive microenvironment in breast cancer. J Leukoc Biol 84: 623-630.
138. PUENTE NAVAZO, M.D., VALMORI, D. and RUEGG, C. (2001). The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production. J Immunol 167: 6431-6440.
139. PUTNAM, N.H., BUTTS, T., FERRIER, D.E., FURLONG, R.F., HELLSTEN, U., KAWASHIMA, T., ROBINSON-RECHAVI, M., SHOGUCHI, E., TERRY, A., YU, J.K. et al. (2008). The amphioxus genome and the evolution of the chordate karyotype. Nature 453: 1064-1071.
140. RAMOS, D.M., CHEN, B., REGEZI, J., ZARDI, L. and PYTELA, R. (1998). Tenascin-C matrix assembly in oral squamous cell carcinoma. Int J Cancer 75: 680-687.
141. RICHARDS, G.S. and DEGNAN, B.M. (2009). The dawn of developmental signaling in the metazoa. Cold Spring Harb Symp Quant Biol 74: 81-90.
142. RIEDL, S., TANDARA, A., REINSHAGEN, M., HINZ, U., FAISSNER, A., BODENMULLER, H., BUHR, H.J., HERFARTH, C. and MOLLER, P. (2001). Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis 16: 285-291.
143. RINKEVICH, Y., ROSNER, A., RABINOWITZ, C., LAPIDOT, Z., MOISEEVA, E. and RINKEVICH, B. (2010). Piwi positive cells that line the vasculature epithelium, underlie whole body regeneration in a basal chordate. Dev Biol 345: 94-104.
144. RIOU, J.F., SHI, D.L., CHIQUET, M. and BOUCAUT, J.C. (1990). Exogenous tenascin inhibits mesodermal cell migration during amphibian gastrulation. Dev Biol 137: 305-317.
145. RISAU, W. (1997). Mechanisms of angiogenesis. Nature 386: 671-674.
146. ROSANO, L., CIANFROCCA, R., MASI, S., SPINELLA, F., DI CASTRO, V., BIROCCIO, A., SALVATI, E., NICOTRA, M.R., NATALI, P.G. and BAGNATO, A. (2009). Beta-arrestin links endothelin A receptor to beta-catenin signaling to induce ovarian cancer cell invasion and metastasis. Proc Natl Acad Sci USA 106: 2806-2811.
147. ROSANO, L., VARMI, M., SALANI, D., DI CASTRO, V., SPINELLA, F., NATALI, P.G. and BAGNATO, A. (2001). Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res 61: 8340-8346.
148. ROTH-KLEINER, M., HIRSCH, E. and SCHITTNY, J.C. (2004). Fetal lungs of tenascin-C-deficient mice grow well, but branch poorly in organ culture. Am J Respir Cell Mol Biol 30: 360-366.
149. ROY, S., CAGLIERO, E. and LORENZI, M. (1996). Fibronectin overexpression in retinal microvessels of patients with diabetes. Invest Ophthalmol Vis Sci 37: 258-266.
150. RUIZ, C., HUANG, W., HEGI, M.E., LANGE, K., HAMOU, M.F., FLURI, E., OAKELEY, E.J., CHIQUET-EHRISMANN, R. and OREND, G. (2004). Growth promoting signaling by tenascin-C [corrected]. Cancer Res 64: 7377-7385.
151. RUPERT, E.E. and CARLE, K.J. (1983). Morphology of metazoan circulatory systems. Zoomorphology 103: 193-208.
152. SAGA, Y., YAGI, T., IKAWA, Y., SAKAKURA, T. and AIZAWA, S. (1992). Mice develop normally without tenascin. Genes Dev 6: 1821-1831.
153. SCHENK, S., CHIQUET-EHRISMANN, R. and BATTEGAY, E.J. (1999). The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. Mol Biol Cell 10: 2933-2943.
154. SCHLIEMANN, C. and NERI, D. (2010). Antibody-based vascular tumor targeting. Recent Results Cancer Res 180: 201-216.
155. SEBE-PEDROS, A., ROGER, A.J., LANG, F.B., KING, N. and RUIZ-TRILLO, I. (2010). Ancient origin of the integrin-mediated adhesion and signaling machinery. Proc Natl Acad Sci USA 107: 10142-10147.
156. SHIELDS, J.D., KOURTIS, I.C., TOMEI, A.A., ROBERTS, J.M. and SWARTZ, M.A. (2010). Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science 328: 749-752.
157. SINGH, P., CARRAHER, C. and SCHWARZBAUER, J.E. (2010). Assembly of Fibronectin Extracellular Matrix. Annu Rev Cell Dev Biol 26: 397-419.
158. SIRI, A., KNAUPER, V., VEIRANA, N., CAOCCI, F., MURPHY, G. and ZARDI, L. (1995). Different susceptibility of small and large human tenascin-C isoforms to degradation by matrix metalloproteinases. J Biol Chem 270: 8650-8654.
159. SOBOCINSKI, G.P., TOY, K., BOBROWSKI, W.F., SHAW, S., ANDERSON, A.O. and KALDJIAN, E.P. (2010). Ultrastructural localization of extracellular matrix proteins of the lymph node cortex: evidence supporting the reticular network as a pathway for lymphocyte migration. BMC Immunol 11: 42.
160. STANCHI, F., GRASHOFF, C., NGUEMENI YONGA, C.F., GRALL, D., FASSLER, R. and VAN OBBERGHEN-SCHILLING, E. (2009). Molecular dissection of the ILK-PINCH-parvin triad reveals a fundamental role for the ILK kinase domain in the late stages of focal-adhesion maturation. J Cell Sci 122: 1800-1811.
161. STOCKMANN, C., DOEDENS, A., WEIDEMANN, A., ZHANG, N., TAKEDA, N., GREENBERG, J.I., CHERESH, D.A. and JOHNSON, R.S. (2008). Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 456: 814-818.
162. TAKAHASHI, S., LEISS, M., MOSER, M., OHASHI, T., KITAO, T., HECKMANN, D., PFEIFER, A., KESSLER, H., TAKAGI, J., ERICKSON, H.P. et al. (2007). The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol 178: 167-178.
163. TALTS, J.F., WIRL, G., DICTOR, M., MULLER, W.J. and FASSLER, R. (1999). Tenascin-C modulates tumor stroma and monocyte/macrophage recruitment but not tumor growth or metastasis in a mouse strain with spontaneous mammary cancer. J Cell Sci 112: 1855-1864.
164. TANAKA, K., HIRAIWA, N., HASHIMOTO, H., YAMAZAKI, Y. and KUSAKABE, M. (2004). Tenascin-C regulates angiogenesis in tumor through the regulation of vascular endothelial growth factor expression. Int J Cancer 108: 31-40.
165. TARASEVICIUTE, A., VINCENT, B.T., SCHEDIN, P. and JONES, P.L. Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol 176: 827-38.
166. TO, W.S. and MIDWOOD, K.S. (2010). Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis. Matrix Biol 29: 573-585.
167. TUCKER, R.P. (1993). The in situ localization of tenascin splice variants and thrombospondin 2 mRNA in the avian embryo. Development 117: 347-358.
168. TUCKER, R.P. and CHIQUET-EHRISMANN, R. (2009). Evidence for the evolution of tenascin and fibronectin early in the chordate lineage. Int J Biochem Cell Biol 41: 424-434.
169. TUCKER, R.P., DRABIKOWSKI, K., HESS, J.F., FERRALLI, J., CHIQUET-EHRISMANN, R. and ADAMS, J.C. (2006). Phylogenetic analysis of the tenascin gene family: evidence of origin early in the chordate lineage. BMC Evol Biol 6: 60.
170. UEMURA, A., KUSUHARA, S., WIEGAND, S.J., YU, R.T. and NISHIKAWA, S. (2006). Tlx acts as a proangiogenic switch by regulating extracellular assembly of fibronectin matrices in retinal astrocytes. J Clin Invest 116: 369-377.
171. VENTURA, E., SASSI, F., PARODI, A., BALZA, E., BORSI, L., CASTELLANI, P., CARNEMOLLA, B. and ZARDI, L. (2010). Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8. PLoS One 5: e9145.
172. VOSSELER, S., MIRANCEA, N., BOHLEN, P., MUELLER, M.M. and FUSENIG, N.E. (2005). Angiogenesis inhibition by vascular endothelial growth factor receptor-2 blockade reduces stromal matrix metalloproteinase expression, normalizes stromal tissue, and reverts epithelial tumor phenotype in surface heterotransplants. Cancer Res 65: 1294-1305.
173. VOURET-CRAVIARI, V., BOULTER, E., GRALL, D., MATTHEWS, C. and VAN OBBERGHEN-SCHILLING, E. (2004). ILK is required for the assembly of matrix-forming adhesions and capillary morphogenesis in endothelial cells. J Cell Sci 117: 4559-4569.
174. WHITE, E.S., BARALLE, F.E. and MURO, A.F. (2008). New insights into form and function of fibronectin splice variants. J Pathol 216: 1-14.
175. WICKI, A., LEHEMBRE, F., WICK, N., HANTUSCH, B., KERJASCHKI, D. and CHRISTOFORI, G. (2006). Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell 9: 261-272.
176. WILSON, K.E., BARTLETT, J.M., MILLER, E.P., SMYTH, J.F., MULLEN, P., MILLER, W.R. and LANGDON, S.P. (1999). Regulation and function of the extracellular matrix protein tenascin-C in ovarian cancer cell lines. Br J Cancer 80: 685-692.
177. WILSON, K.E., LANGDON, S.P., LESSELLS, A.M. and MILLER, W.R. (1996). Expression of the extracellular matrix protein tenascin in malignant and benign ovarian tumours. Br J Cancer 74: 999-1004.
178. YANG, J.T., RAYBURN, H. and HYNES, R.O. (1993). Embryonic mesodermal defects in alpha 5 integrin-deficient mice. Development 119: 1093-1105.
179. YOKOSAKI, Y., MATSUURA, N., HIGASHIYAMA, S., MURAKAMI, I., OBARA, M., YAMAKIDO, M., SHIGETO, N., CHEN, J. and SHEPPARD, D. (1998). Identification of the ligand binding site for the integrin alpha9 beta1 in the third fibronectin type III repeat of tenascin-C. J Biol Chem 273: 11423-11428.